Hervé Dombret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hervé Dombret has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Claude Preudhomme
Chru of Lille, Lille, France
6 shared publications Xavier Thomas
6 shared publications- Emmanuel Raffoux
Saint Louis Hospital, Hematology Department, Paris, France
5 shared publications Laurent Degos
Department of Hematology, St Louis Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 7, Paris, France
4 shared publications- Nicolas Boissel
Département d’Hématologie, Hôpital Saint-Louis, EA3518, Institut Universitaire d’Hématologie, Université Paris 7, France
4 shared publications - Norbert Ifrah
Institut National du Cancer, Boulogne-Billancourt, France
4 shared publications
Latest Publications
- Top Cited Papers
- 15 September 2016
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 375 (11) , 1044-1053
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Treatment with rituximab has improved the outcome for patients with non-Hodgkin’s lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial.
- 15 September 2016
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 375 (11) , 1044-1053
Top Cited PapersRituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Treatment with rituximab has improved the outcome for patients with non-Hodgkin’s lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial.
- 3 June 2016
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 19 (11) , 1034-1039
Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review
Objective: Philadelphia chromosome negative [Ph(−)] relapsed or refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) is an extremely rare condition requiring intensive treatment. This retrospective chart review aimed to quantify hospitalizations and reimbursement in this patient population in France. Methods: Patients aged ≥18 years and with at least one hospitalization for Ph(−) R/R B-precursor ALL were included in the study. They were relapsed with first remission lasting <12 months, relapsed after first salvage therapy, relapsed any time after hematopoietic stem cell transplant (HSCT), or were refractory to initial or salvage therapy. Data were collected from the index date (first diagnosis of R/R ALL) until death or loss to follow-up. The chemotherapy period was defined as the first chemotherapy date after the index date to the earliest of death, loss to follow-up, last chemotherapy dose plus 30 days, or initiation of HSCT. The primary outcome was the percentage of time hospitalized during the chemotherapy period. Results: Thirty-three patients were included, with a mean age of 49 years. The mean proportion of time spent in the hospital during the chemotherapy period was 46% (95% CI =34–57%). Patients had a mean of 2.2 (SD =1.5) inpatient hospitalizations and the mean length of stay per hospitalization was 16.8 (SD =14.8) days. During the chemotherapy period, the mean amount reimbursed per hospitalization was €31 067 (SD = €4850) and the total hospitalization reimbursement per patient was €68 344. From the index date to death, excluding HSCT, the total reimbursement per patient was €108 873. Limitations: The sample size was small, although this was expected given the rarity of the patient population. Conclusions: Adults with Ph(−) R/R B-precursor ALL had repeated and prolonged hospitalizations during salvage chemotherapy. Approximately half the follow-up period was spent in the hospital, and this time was associated with high economic burden in France.
- 3 June 2016
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 19 (11) , 1034-1039
Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review
Objective: Philadelphia chromosome negative [Ph(−)] relapsed or refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) is an extremely rare condition requiring intensive treatment. This retrospective chart review aimed to quantify hospitalizations and reimbursement in this patient population in France. Methods: Patients aged ≥18 years and with at least one hospitalization for Ph(−) R/R B-precursor ALL were included in the study. They were relapsed with first remission lasting <12 months, relapsed after first salvage therapy, relapsed any time after hematopoietic stem cell transplant (HSCT), or were refractory to initial or salvage therapy. Data were collected from the index date (first diagnosis of R/R ALL) until death or loss to follow-up. The chemotherapy period was defined as the first chemotherapy date after the index date to the earliest of death, loss to follow-up, last chemotherapy dose plus 30 days, or initiation of HSCT. The primary outcome was the percentage of time hospitalized during the chemotherapy period. Results: Thirty-three patients were included, with a mean age of 49 years. The mean proportion of time spent in the hospital during the chemotherapy period was 46% (95% CI =34–57%). Patients had a mean of 2.2 (SD =1.5) inpatient hospitalizations and the mean length of stay per hospitalization was 16.8 (SD =14.8) days. During the chemotherapy period, the mean amount reimbursed per hospitalization was €31 067 (SD = €4850) and the total hospitalization reimbursement per patient was €68 344. From the index date to death, excluding HSCT, the total reimbursement per patient was €108 873. Limitations: The sample size was small, although this was expected given the rarity of the patient population. Conclusions: Adults with Ph(−) R/R B-precursor ALL had repeated and prolonged hospitalizations during salvage chemotherapy. Approximately half the follow-up period was spent in the hospital, and this time was associated with high economic burden in France.
- Top Cited Papers
- 1 April 2016
- Published by Elsevier in The Lancet Haematology
- Vol. 3 (4) , e186-e195
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- 1 April 2016
- Published by Elsevier in The Lancet Haematology
- Vol. 3 (4) , e186-e195
Top Cited PapersBromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- Top Cited PapersOpen Access
- 16 July 2015
- Published by American Society of Hematology in Blood
- Vol. 126 (3) , 291-299
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Key Points: Azacitidine increased median overall survival by 3.8 months vs current commonly used AML treatments (10.4 vs 6.5 months; P = .1009). Azacitidine safety in patients age ≥65 years with AML (>30% blasts) was consistent with its known safety profile in other trials.
- 16 July 2015
- Published by American Society of Hematology in Blood
- Vol. 126 (3) , 291-299
Top Cited PapersOpen AccessInternational phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Key Points: Azacitidine increased median overall survival by 3.8 months vs current commonly used AML treatments (10.4 vs 6.5 months; P = .1009). Azacitidine safety in patients age ≥65 years with AML (>30% blasts) was consistent with its known safety profile in other trials.
- 10 June 2015
- Published by Wiley in British Journal of Haematology
- Vol. 172 (4) , 628-630
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms
- 10 June 2015
- Published by Wiley in British Journal of Haematology
- Vol. 172 (4) , 628-630
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms
- 15 May 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (1) , 199-200
UnlikeASXL1andASXL2mutations,ASXL3mutations are rare events in acute myeloid leukemia with t(8;21)
- 15 May 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (1) , 199-200
UnlikeASXL1andASXL2mutations,ASXL3mutations are rare events in acute myeloid leukemia with t(8;21)
- Open Access
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French‐Belgian‐Swiss APL group
BACKGROUND Reports of patients with secondary acute promyelocytic leukemia (APL) have increased in recent years, particularly for those who received treatment with mitoxantrone, and retrospective studies have suggested that their characteristics and outcomes were similar to those of patients with de novo APL. METHODS The authors investigated patients with de novo and secondary APL who were included in the ongoing APL-2006 trial. Patients with secondary APL who were included in that trial also were compared with a previous retrospective cohort of patients with secondary APL. RESULTS In the APL-2006 trial, 42 of 280 patients (15%) had secondary APL. Compared with the retrospective cohort, patients with secondary APL in the APL-2006 trial had a lower incidence of prior breast carcinoma (35.7% vs 57%; P = .03) and a higher incidence of prior prostate carcinoma (26.2% vs 4.7%; P < .001). Treatment of the primary tumor in the APL-2006 trial less frequently included combined radiochemotherapy (28.6% vs 47.2%; P = .044) and no mitoxantrone (0% vs 46.7%; P = .016) but more frequently included anthracyclines (53.3% vs 38.3%; P = .015). In the APL-2006 trial, patients who had secondary APL, compared with those who had de novo APL, were older (mean, 60.2 years vs 48.7 years, respectively; P < .0001) but had a similar complete response rate (97.6% vs 90.3%, respectively), cumulative incidence of relapse (0% vs 1.8%, respectively), and overall survival (92.3% vs 90.9%, respectively) at 18 months. CONCLUSIONS Although the incidence of secondary APL appears to be stable over time, evolving strategies for the treatment of primary cancers have reduced its occurrence among breast cancer patients but have increased its incidence among patients with prostate cancer. The current results confirm prospectively that patients with secondary APL have characteristics and outcomes similar to those of patients with de novo APL. Cancer 2015;121:2393–2399. © 2015 American Cancer Society.
Open AccessEvolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French‐Belgian‐Swiss APL group
BACKGROUND Reports of patients with secondary acute promyelocytic leukemia (APL) have increased in recent years, particularly for those who received treatment with mitoxantrone, and retrospective studies have suggested that their characteristics and outcomes were similar to those of patients with de novo APL. METHODS The authors investigated patients with de novo and secondary APL who were included in the ongoing APL-2006 trial. Patients with secondary APL who were included in that trial also were compared with a previous retrospective cohort of patients with secondary APL. RESULTS In the APL-2006 trial, 42 of 280 patients (15%) had secondary APL. Compared with the retrospective cohort, patients with secondary APL in the APL-2006 trial had a lower incidence of prior breast carcinoma (35.7% vs 57%; P = .03) and a higher incidence of prior prostate carcinoma (26.2% vs 4.7%; P < .001). Treatment of the primary tumor in the APL-2006 trial less frequently included combined radiochemotherapy (28.6% vs 47.2%; P = .044) and no mitoxantrone (0% vs 46.7%; P = .016) but more frequently included anthracyclines (53.3% vs 38.3%; P = .015). In the APL-2006 trial, patients who had secondary APL, compared with those who had de novo APL, were older (mean, 60.2 years vs 48.7 years, respectively; P < .0001) but had a similar complete response rate (97.6% vs 90.3%, respectively), cumulative incidence of relapse (0% vs 1.8%, respectively), and overall survival (92.3% vs 90.9%, respectively) at 18 months. CONCLUSIONS Although the incidence of secondary APL appears to be stable over time, evolving strategies for the treatment of primary cancers have reduced its occurrence among breast cancer patients but have increased its incidence among patients with prostate cancer. The current results confirm prospectively that patients with secondary APL have characteristics and outcomes similar to those of patients with de novo APL. Cancer 2015;121:2393–2399. © 2015 American Cancer Society.
- 1 April 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (4) , 453-461
The p16INK4A/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome
- 1 April 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (4) , 453-461
The p16INK4A/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome
- 1 January 2015
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 7 (1)
0195: Identification of patients (pts) with chronic myeloid leukemia (CML) at high risk of artery occlusive events (AOE) during treatment with the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib
- 1 January 2015
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 7 (1)
0195: Identification of patients (pts) with chronic myeloid leukemia (CML) at high risk of artery occlusive events (AOE) during treatment with the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib